Aiolos Bio: GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
Read full article »
Aiolos Bio is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for respiratory and inflammatory diseases.
Read more